IMMUNOGENICITY IN PRECLINICAL DRUG DEVELOPMENT: STRATEGIES, RISKS, AND IMPLICATIONS FOR LARGE MOLECULE-BASED BIOLOGICS INCLUDING CAR T-CELL AND GENE THERAPIES

Main Article Content

Sagarkumar Patel
Rachna Patel
Ashok Akabari

Keywords

.

Abstract

Immunogenicity is a critical consideration in developing therapeutic agents, particularly in large molecule-based biologics, CAR T-cell therapies, and gene therapies. This comprehensive review delves into the multifaceted landscape of immunogenicity, elucidating its definition and significance in drug development. Immunogenicity encompasses the complex interplay between therapeutic agents and the immune system, posing opportunities and challenges. It necessitates a nuanced approach to assessment, explored in detail, including the methods and tools employed during preclinical development and the vital role of predictive immunogenicity assays. Factors contributing to immunogenicities, such as protein structure, post-translational modifications, and patient-related variables, are dissected, shedding light on the intricate determinants of immune responses.


 


Moreover, the review explores how immunogenicity can profoundly impact pharmacokinetics and pharmacodynamics, substantiated by real-world cases. Risk mitigation strategies are a focal point, emphasizing the importance of protein engineering, formulation development, and the judicious use of immunosuppressive therapies. The review further addresses the unique challenges posed by CAR T-cell therapies and gene therapies, highlighting their distinctive immunogenicity considerations. Regulatory guidelines governing immunogenicity assessment and the imperative of addressing this aspect in regulatory submissions are also discussed. Finally, the review provides a series of case studies, offering tangible examples of how immunogenicity has influenced drug development, encompassing successful strategies and encountered challenges. Future directions in immunogenicity research promise to shape the landscape of therapeutic effect, with implications for precision medicine and patient-centric care.

Abstract 123 | pdf Downloads 62

References

1. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MAbs [Internet]. 2010 [cited 2023 Sep 9];2:256–65. Available from: /pmc/articles/PMC2881252/
2. Akabari AH, Patel S, Vaghela N, Ramani V, Shah DP. Recent Application of Nanotechnology for Cancer Immunotherapy and Its Future Prospects. Int J Immunol Immunother. 2023;10:69.
3. Hanna E, Rémuzat C, Auquier P, Toumi M. Gene therapies development: slow progress and promising prospect. J Mark Access Heal Policy [Internet]. 2017 [cited 2023 Sep 9];5:1265293. Available from: /pmc/articles/PMC5328344/
4. Shakhnovich V, Meibohm B, Rosenberg A, Kierzek AM, Hasenkamp R, Funk RS, et al. Immunogenicity in Clinical Practice and Drug Development: When is it Significant? [Internet]. Clin. Transl. Sci. Wiley-Blackwell; 2020 [cited 2023 Sep 9]. p. 219–23. Available from: /pmc/articles/PMC7070797/
5. Ilinskaya AN, Dobrovolskaia MA. Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. Toxicol Appl Pharmacol [Internet]. 2016 [cited 2023 Sep 9];299:70–7. Available from: /pmc/articles/PMC4811736/
6. Sauna ZE, Jawa V, Balu-Iyer S, Chirmule N. Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development. Front. Immunol. Frontiers Media S.A.; 2023. p. 1151888.
7. Emea. Committee For Medicinal Products For Human Use (CHMP) Draft Guideline On Immunogenicity Assessment Of Biotechnology-Derived Therapeutic Proteins Draft Agreed By BMWP [Internet]. 2006. Available from: www.ema.europa.eu/contact
8. Rosenberg AS, Sauna ZE. Immunogenicity assessment during the development of protein therapeutics [Internet]. J. Pharm. Pharmacol. John Wiley & Sons, Ltd; 2018 [cited 2023 Sep 10]. p. 584–94. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/jphp.12810
9. Dingman R, Balu-Iyer S V. Immunogenicity of Protein Pharmaceuticals [Internet]. J. Pharm. Sci. NIH Public Access; 2019 [cited 2023 Sep 10]. p. 1637–54. Available from: /pmc/articles/PMC6720129/
10. Dimitrov DS. Therapeutic proteins. Methods Mol Biol [Internet]. 2012 [cited 2023 Sep 10];899:1–26. Available from: /pmc/articles/PMC6988726/
11. Pineda C, Castañeda Hernández G, Jacobs IA, Alvarez DF, Carini C. Assessing the Immunogenicity of Biopharmaceuticals [Internet]. BioDrugs. Springer; 2016 [cited 2023 Sep 10]. p. 195–206. Available from: /pmc/articles/PMC4875071/
12. Potthoff B, McBlane F, Spindeldreher S, Sickert D. A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel. J Immunol Methods. 2020;476:112692.
13. Beeg M, Nobili A, Orsini B, Rogai F, Gilardi D, Fiorino G, et al. A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. Sci Rep [Internet]. 2019 [cited 2023 Sep 10];9. Available from: /pmc/articles/PMC6376047/
14. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant [Internet]. 2005 [cited 2023 Sep 10];20:3–9. Available from: https://academic.oup.com/ndt/article/20/suppl_6/vi3/1889557
15. Aryal S. Factors affecting Immunogenicity - Microbe Notes [Internet]. 2021 [cited 2023 Sep 10]. Available from: https://microbenotes.com/factors-affecting-immunogenicity/
16. Smith A, Manoli H, Jaw S, Frutoz K, Epstein AL, Khawli LA, et al. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. J. Immunol. Res. Hindawi Limited; 2016.
17. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: Impact on PK/PD and efficacy [Internet]. AAPS J. Springer; 2012 [cited 2023 Sep 10]. p. 296–302. Available from: /pmc/articles/PMC3326159/
18. Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn BC. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments [Internet]. Front. Immunol. Frontiers Media SA; 2022 [cited 2023 Sep 10]. Available from: /pmc/articles/PMC9355792/
19. NCI Editors. CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI [Internet]. Natl. Cancer Inst. 2022 [cited 2023 Sep 10]. p. 1–6. Available from: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
20. Vandivort TC, Horton DB, Johnson SB. Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs. J Clin Transl Sci [Internet]. 2020 [cited 2023 Sep 10];4:547–55. Available from: /pmc/articles/PMC8057416/
21. Varin J, Morival C, Maillard N, Adjali O, Cronin T. Risk mitigation of immunogenicity: A key to personalized retinal gene therapy [Internet]. Int. J. Mol. Sci. Multidisciplinary Digital Publishing Institute (MDPI); 2021 [cited 2023 Sep 10]. p. 22. Available from: /pmc/articles/PMC8658027/
22. Yang T yuan, Braun M, Lembke W, McBlane F, Kamerud J, DeWall S, et al. Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper [Internet]. Mol. Ther. - Methods Clin. Dev. Elsevier; 2022 [cited 2023 Sep 10]. p. 471–94. Available from: http://www.cell.com/article/S2329050122001103/fulltext
23. Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front. Immunol. Frontiers Media S.A.; 2022. p. 975803.
24. FDA. International Regulatory Harmonization | FDA [Internet]. 2020 [cited 2023 Sep 10]. Available from: https://www.fda.gov/drugs/cder-international-program/international-regulatory-harmonization
25. Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: A review [Internet]. Autoimmun. Rev. Autoimmun Rev; 2005 [cited 2023 Sep 10]. p. 144–52. Available from: https://pubmed.ncbi.nlm.nih.gov/15823500/
26. Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R, Chimenti S, et al. Adalimumab in the Treatment of Immune-Mediated Diseases [Internet]. Int. J. Immunopathol. Pharmacol. Int J Immunopathol Pharmacol; 2014 [cited 2023 Sep 10]. p. 33–48. Available from: https://pubmed.ncbi.nlm.nih.gov/24774505/
27. Introduction - Clinical Review Report: Migalastat (Galafold) - NCBI Bookshelf [Internet]. [cited 2023 Sep 10]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567517/
28. Guttmann A, Krasnokutsky S, Pillinger MH, Berhanu A. Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations [Internet]. Ther. Adv. Drug Saf. SAGE Publications; 2017 [cited 2023 Sep 10]. p. 379–88. Available from: /pmc/articles/PMC5703101/
29. Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv. Drug Deliv. Rev. Elsevier; 2020. p. 163–75.
30. Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases [Internet]. Drugs. Drugs; 2014 [cited 2023 Sep 10]. p. 1379–410. Available from: https://pubmed.ncbi.nlm.nih.gov/25034360/
31. Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, et al. Therapeutic peptides: current applications and future directions [Internet]. Signal Transduct. Target. Ther. Nature Publishing Group; 2022 [cited 2023 Sep 10]. p. 1–27. Available from: https://www.nature.com/articles/s41392-022-00904-4